EP3429568A1 - Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications - Google Patents
Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complicationsInfo
- Publication number
- EP3429568A1 EP3429568A1 EP17808579.1A EP17808579A EP3429568A1 EP 3429568 A1 EP3429568 A1 EP 3429568A1 EP 17808579 A EP17808579 A EP 17808579A EP 3429568 A1 EP3429568 A1 EP 3429568A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- substantially equal
- beta
- less
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 title claims description 60
- 201000011510 cancer Diseases 0.000 title claims description 39
- 238000011282 treatment Methods 0.000 title claims description 28
- 230000001225 therapeutic effect Effects 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 59
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 claims abstract description 50
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims abstract description 30
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims abstract description 29
- BSDNZCQPDVTDET-HWKANZROSA-N (E)-3-(2-Hydroxyphenyl)-2-propenal Chemical compound OC1=CC=CC=C1\C=C\C=O BSDNZCQPDVTDET-HWKANZROSA-N 0.000 claims abstract description 27
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- BSDNZCQPDVTDET-UHFFFAOYSA-N 2-hydroxy cinnamaldehyde Natural products OC1=CC=CC=C1C=CC=O BSDNZCQPDVTDET-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 23
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 23
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 23
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 23
- 229950005143 sitosterol Drugs 0.000 claims abstract description 23
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 16
- 229940117916 cinnamic aldehyde Drugs 0.000 claims abstract description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 14
- 239000004148 curcumin Substances 0.000 claims abstract description 7
- 235000012754 curcumin Nutrition 0.000 claims abstract description 7
- 229940109262 curcumin Drugs 0.000 claims abstract description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 31
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 22
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 102100027092 RuvB-like 2 Human genes 0.000 claims description 13
- 108050002976 RuvB-like helicase 2 Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 102000000763 Survivin Human genes 0.000 claims description 9
- 108010002687 Survivin Proteins 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 108091006082 receptor inhibitors Proteins 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000005754 cellular signaling Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 2
- 229960004176 aclarubicin Drugs 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims description 2
- 238000002725 brachytherapy Methods 0.000 claims description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 2
- 235000008207 calcium folinate Nutrition 0.000 claims description 2
- 239000011687 calcium folinate Substances 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000037417 hyperactivation Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 230000007115 recruitment Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- QRGLVSPIIXTSIE-UHFFFAOYSA-N BCA Natural products O=CC=CC1=CC=CC=C1OC(=O)C1=CC=CC=C1 QRGLVSPIIXTSIE-UHFFFAOYSA-N 0.000 abstract description 14
- QRGLVSPIIXTSIE-UXBLZVDNSA-N [2-[(e)-3-oxoprop-1-enyl]phenyl] benzoate Chemical compound O=C\C=C\C1=CC=CC=C1OC(=O)C1=CC=CC=C1 QRGLVSPIIXTSIE-UXBLZVDNSA-N 0.000 abstract description 14
- 230000009471 action Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- -1 As4S4 Chemical compound 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YVILHAWRFSLJKQ-UHFFFAOYSA-N (3-oxo-1-phenylprop-1-en-2-yl) benzoate Chemical compound C=1C=CC=CC=1C=C(C=O)OC(=O)C1=CC=CC=C1 YVILHAWRFSLJKQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011229 conventional cytotoxic chemotherapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- composition used for the therapeutic treatment of cancer and its complications.
- the present invention relates to a pharmaceutical composition which can be used as a medicament, in particular for the therapeutic treatment of cancers and in particular hepatocellular carcinoma.
- HCC hepatocellular carcinoma
- VEGF inhibitors vascular endothelial growth factor
- VEGF vascular endothelial growth factor
- EGFR Receptor Extracellular Growth Factor Receptor
- Inhibitors of Several Tyrosine Kinase-Activating Receptors That Parallelize Cellular Angiogenesis and Proliferation Kinase Inhibitors, IGF-IR Receptor Inhibitors, Inhibitors of mTOR and inhibitors of the MEK-ERK signaling pathway.
- biomarkers have been validated for breast cancer (HER copy number), lung cancer (EGFR mutations) or colon cancer (Kras mutations), there are currently no biomarkers Validated prognostic for HCC under targeted therapy.
- reptin and / or pontine are overexpressed during carcinogenesis; their nucleo-cytoplasmic localization was variable according to the type of cancer and was not necessarily a factor of poor prognosis.
- overexpression of reptin and pontine is a poor prognostic factor in HCCs and a high level of pontine mRNA correlates poor prognosis [(Haurie et al., 2009). Hepatology. 2009 Dec; 50 (6): 1871-83. doi: 10.1002 / hep.23215].
- reptin is overexpressed in prostate cancer, hepatocellular carcinoma (HCC), gastric cancer, kidney cancer and breast cancer.
- pontine is overexpressed in hepatocellular carcinoma, lung cancer and colorectal cancer.
- the dysfunction of reptin and / or pontine has also been demonstrated in other cancers such as chronic leukemia, mesothelioma and multiple myeloma, high grade lymphoma, Burkitt's lymphoma, brain tumors such as gliomas and tumors of the bladder.
- Survivin is also known as a therapeutic target in the case of cancer.
- the majority of solid tumors (breast cancer, prostate, lung, kidney, ... etc.) or hematopoietic tumors (multiple myeloma, leukemia, ... etc.) express it aberrantly. It is also known that cancerous breast, lung and kidney tumor cells overexpress survivin.
- beta-elemene can be used as anti-cancer. It has, moreover, a broad antineoplastic spectrum, including the tumors resistant to anticancer drugs conventionally used. It is also known to be non-cytotoxic and well tolerated by patients. It can pass the blood-brain barrier and has immunostimulatory properties. Its anti-inflammatory activity is also known. It is also known that beta-elemene inhibits survivin. It is also known to reduce or even suppress the resistance of cancer cells to anti-cancer drugs.
- beta-elemene also reduces the resistance of cancer cells to certain drugs. Thus, it significantly inhibits MDR1, MRP and GST-JL Chen et al., (2006) (Journal of Medicinal Plants Research Vol.6 (46), pp. 5720-5729, December 3, 2012) have shown that ⁇ -Elémene inevitably increases the intracellular accumulation of AMD in U251 / AMD cells (cells that have developed resistance to AMD) of human glioblastoma, reduces the IC50 of U251 / AMD cells from 0.915 to 0.051 mg / 1.
- lupeol also known as Fagarsterol or Clerodol
- Fagarsterol is a pharmacologically active compound with anti-inflammatory, anti-cancer properties including its antiproliferative activity, regulation cell cycle, apoptosis, angiogenesis and its effect on the epithelial-mesenchymal transition. It also stimulates the immune system of cancer patients.
- lupeol at the effective therapeutic dose shows no toxicity to normal cells and tissues.
- CHC lupeol is known to inhibit BD F protein (Brain-
- Lupeol inhibits HCCLM3 cell proliferation in CHC as a function of concentration and time through Caspase-3 activation and PARP [poly (ADP-ribose) polymerase] cleavage.
- cinnamaldehydes in particular, cinnamaldehyde (CA), 2-hydroxycinnamaldehyde (HCA), and 2-benzoyloxycinnamaldehyde (BCA), a semisynthetic derivative of HCA, each have an anti-inflammatory, anti-inflammatory activity. proliferative, anti-angiogenic, anti-metastatic via inhibition of TEM (epithelio-mesenchymal transition) and pro-apoptotic on many human cancer cells such as melanoma, breast cancer, lung cancer, cancer of the lung ovarian, colon cancer, prostate cancer, myeloma and leukemia.
- CA cinnamaldehyde
- HCA 2-hydroxycinnamaldehyde
- BCA 2-benzoyloxycinnamaldehyde
- HCA has an effect on HCC.
- Moon EY. (Eun-Yi Moon et al., (2005) European Journal of Pharmacology 530 (2006) 270-275) investigated the inhibitory effect of HCA on farnesyl transferase.
- H-rasl2V a model mouse that developed hepatocellular carcinoma following a transgenic mutation H-rasl2V and under the control of a specific promoter such as albumin.
- HCA / BCA significantly reduces the number and size of liver damage.
- HCA / BCA increases the number of splenocytes and infiltration of lymphocytes in the liver.
- beta-sitosterol is known to possess anti-inflammatory, antipyretic, antineoplastic and immunomodulatory properties.
- An object of the present invention is to provide a novel pharmaceutical composition that can be used as a medicament and more particularly that can be used in the treatment of cancer.
- Another object of the invention is to provide a new pharmaceutical composition that can be used as a medicament and more particularly that can be used in the treatment of cancer that overcomes all or some of the disadvantages related to the compositions of the aforementioned prior art.
- Another object of the invention is to provide a pharmaceutical composition which is particularly advantageous in the treatment of HCC.
- Another object of the present invention is to provide a pharmaceutical composition that can be used as a medicament, in particular for the therapeutic treatment of HCC, of hepatocellular insufficiency and in particular of cirrhosis of the liver.
- Another object of the present invention is to provide a pharmaceutical composition for use in the treatment of breast cancer and / or prostate cancer.
- Another object of the present invention is to provide a pharmaceutical composition which acts specifically on cancer cells which overexpress at least one protein selected from the group consisting of reptin, pontine and survivin and in particular which acts on cells cancerous overexpressing reptin and pontine and possibly survivin.
- Another object of the present invention is to provide a pharmaceutical composition which makes it possible to inhibit the formation of tumor stroma, the metastatic process, to reduce the risk of tumor recurrence.
- Another object of the present invention is to provide a pharmaceutical composition which makes it possible to inhibit inflammation, alteration of the intestinal mucosa, bacterial, viral or fungal translocation of the intestinal lumen to the bloodstream, immune hyperactivation. systemic, to induce a vigorous immune response, particularly in the lymphoid tissue associated with the digestive tract.
- the present invention provides a pharmaceutical composition, which typically comprises, as active ingredient, a combination of beta-elemene, lupeol and a pharmaceutical agent.
- the active ingredient is cinnamaldehyde, 2-hydroxycinnamaldehyde, 2'-benzoyloxycinnalmaldehyde, beta-sitosterol, curcumin and mixtures thereof.
- the Applicant has also demonstrated a synergistic effect of at least two of the constituents which provides a reinforced action of the composition of the invention on at least one mechanism involved in the cancer phenomenon, namely a mechanism chosen from the formation of the tumor stroma, cell growth, apoptosis, angiogenesis, the process metastatic, activation of cellular signaling pathways involved in inflammation, lipid metabolism, carbohydrate, bacterial, viral and fungal infection.
- composition according to the invention has an effect on cells overexpressing reptin and / or pontine, which is the case of the cancer cells of the majority of cancers, including HCC, cancer breast and prostate.
- composition according to the invention inhibits certain axes, in particular CXCR4 / CXCL12, which play a fundamental role in proliferation, tumor growth, metastasis and the formation of an immunosuppressive microenvironment.
- composition of the invention can be used as a medicament and especially for its use in the therapeutic treatment of cancer.
- the composition of the invention may furthermore comprise a mixture of beta-sitosterol and cinnamaldehyde or a mixture of beta-sitosterol and 2-hydroxycinnamaldehyde or a mixture of beta-sitosterol and 2'-benzoyloxycinnamaldehyde or a mixture of cinnamaldehydes including cinnamaldehyde with one or more of its synthetic derivatives and / or metabolites.
- it does not include a mixture of 2-hydroxycinnamaldehyde, 2'-benzoyloxycinnalmaldehyde and beta-sitosterol.
- it may comprise, as a mass percentage of the total mass of the active ingredients, a mass percentage of lupeol substantially equal to or greater than 15% and substantially equal to or less than 55, and in particular substantially equal to or greater than 30% o and substantially equal to or less than 50%, a percentage of beta-elemene substantially equal to or greater than 10%> and substantially equal to or less than 55%, and especially substantially equal to or greater than 20% and substantially equal to or less than 40%, a percentage of cinnamaldehyde substantially equal to or greater than 10% and substantially equal to or less than 45%), and in particular substantially equal to or greater than 20% and substantially equal to or less than 40%), a percentage of 2-hydroxycinnamaldehyde substantially equal to or greater than at 10% and substantially equal to or less than 45%, and especially substantially equal to or greater than 20% and substantially equal to or less than 40%, a percentage of 2'-benzoyloxycinnalmaldéhyde substantially equal to or greater than 10% and substantially equal to or less than 45%, and especially
- composition comprises cinnamaldehyde and one of its derivatives
- their weight percentage relative to the total mass of the active ingredients is especially equal and in particular substantially equal to 20%.
- composition according to the invention further comprises at least one pharmaceutically acceptable excipient.
- This excipient can be solid or liquid. It may be chosen, for example, from purified water, ethyl alcohol, propylene glycol, glycerin, vegetable oils, animal oils, hydrocarbons, silicones, sugars such as glucose, levulose, wheat starch, corn starch, potato starch, xanthan gum, gum arabic, gum tragacanth, gum Sterculia, guar gum or "guaranates", pectins, alginates carrageenates, agar agar or agar, gelatin, cellulose and its derivatives.
- composition of the invention may be administered by any suitable route, for example by oral, rectal, local (topical, for example), intraperitoneal, systemic, intravenous, intramuscular, subcutaneous or mucosal, especially sublingual or using a patch, or in encapsulated form, or immobilized on liposomes, microparticles, microcapsules, associated with nanoparticles and the like.
- compositions can advantageously be administered orally by intravenous injection.
- excipients suitable for oral administration talc, lactose, starch and its derivatives, cellulose and its derivatives, polyethylene glycols, polymers of acrylic acid, gelatin, magnesium stearate, animal, vegetable or synthetic fats, paraffin derivatives, glycols, stabilizers, preservatives, antioxidants, wetting agents, anti-caking agents, dispersants, emulsifiers , taste modifying agents, penetrating agents, solubilizing agents.
- the techniques of formulation and administration of drugs and pharmaceutical compositions are well known in the art here considered, the skilled person may in particular refer to the book Remington's Pharmaceutical Sciences, latest edition. According to the invention, the composition can advantageously be administered orally by intravenous injection.
- composition according to the invention is adapted to be administered orally or intravenously at a dose substantially equal to or greater than 40 mg / kg / 24h and substantially equal to or less than 200 mg / kg / 24h in one or more doses. a mammal with such a need.
- the composition of the invention may be used in the therapeutic treatment of a cancer selected from hepatocellular carcinoma, colon cancer, rectal cancer, stomach cancer, cancer of the mouth, including cancer of the tongue, prostate cancer, metastatic prostate cancer, kidney cancer, breast cancer, chemoresistant breast cancer, bladder cancer, leukemia in chronic form or acute, multiple myeloma, lymphoma, brain tumors, lung cancer, especially lung adenocarcinoma, uterine cancer, ovarian cancer, bone tumors, pancreatic cancer, gall bladder cancer and liver cancer.
- a cancer selected from hepatocellular carcinoma, colon cancer, rectal cancer, stomach cancer, cancer of the mouth, including cancer of the tongue, prostate cancer, metastatic prostate cancer, kidney cancer, breast cancer, chemoresistant breast cancer, bladder cancer, leukemia in chronic form or acute, multiple myeloma, lymphoma, brain tumors, lung cancer, especially lung adenocarcinoma, uterine cancer, ovarian cancer, bone tumors, pancreatic cancer,
- composition according to the invention can advantageously be used in patients suffering from a chronic inflammatory disease and in particular, in inflammatory bowel diseases, more particularly ulcerative colitis, in patients carrying a pathogenic agent capable of to induce inflammation, in particular, Helicobacter pylori, in patients with diabetes, dyslipidemia, osteoarticular disorders, patients with hepatocellular insufficiency, patients with bacterial, fungal or viral infections, in particular patients with hepatitis B virus and / or hepatitis C and / or acquired immunodeficiency virus (HIV).
- CHC the Applicant has demonstrated that the composition according to the invention gave good results at least in vitro and showed no toxicity to the liver cells of the patient.
- composition of the invention can be used in the therapeutic treatment of cancer as an agent blocking the recruitment of bone marrow stem cells to the bone marrow.
- This mechanism would be by destructuring, a restructuring of the lipid composition of the cell membranes, and thereby inhibit the cell signaling pathways involved in metabolic diseases, the secretion of inflammatory cytokines, chemokines, cell proliferation, and cell proliferation. angiogenesis, metastasis, and in bacterial, viral or fungal infection.
- the present invention also relates to a pharmaceutical preparation which comprises the composition according to the invention, and, in addition, as a mixture or separately packaged, at least one anti-cancer agent for their use in the therapeutic treatment of cancer simultaneously, sequentially or spaced in time.
- the anticancer agent may be chosen from the inhibitors of
- VEGF vascular endothelial growth factor
- EGFR receptor blockers multiple tyrosine kinase receptor inhibitors that simultaneously target angiogenesis and cell proliferation, kinase inhibitors, IGF-1R receptor inhibitors, mTOR inhibitors, inhibitors of the MEK-ERK signaling pathway, paclitaxel, As4S4, tamoxifen, curcumin, vincristine, adriamycin, aclarubicin, oxaliplatin, calcium folinate, 5-fluorouracil, capecitabine, cisplatin , tetramethylpyrazine, methotrexate, daunorubicin, certain genetically modified viruses which preferentially target cancer cells and mixtures thereof, and in particular mixtures of two of said anti-cancer agents, radioactive agents which can be used in brachytherapy and / or injectable or unmanageable.
- the present invention also relates to a pharmaceutical preparation which comprises in combination beta-elemene, lupeol and / or beta-sitosterol, cinnamaldehyde and / or 2-hydroxycinnamaldehyde and / or 2'-benzoyloxycinnamaldehyde and optionally curcumin.
- the present invention also relates to a dietary supplement which comprises, in combination, beta-elemene, lupeol and / or beta-sitosterol and a pharmaceutically active agent chosen from cinnamaldehyde, 2-hydroxycinnamaldehyde, 2'-benzoyloxycinnalmaldehyde and mixtures thereof and optionally curcumin.
- therapeutic treatment refers to curative treatment and prophylactic treatment; within the meaning of the present invention, a therapeutic treatment makes it possible to at least partially restore, at least partially correct or at least partially modify physiological functions by exerting a pharmacological, immunological or metabolic action.
- patient refers to an animal or human mammal.
- composition according to the invention can also be used in veterinary medicine.
- an "anti-cancer agent” is an element that has, at least in vitro, an action against cancer cells, regardless of its mechanism of action.
- action means the destruction or at least partial modification of the cancer cells, which makes it possible in particular to limit the proliferation of the cancer cells and / or their propagation.
- patients with diabetes refers to patients with type 1 diabetes, patients with type 2 diabetes, patients with gestational diabetes, patients with diabetes insipidus and patients with renal diabetes.
- dislipidemia refers to hyperlipidemia and hypolipidemia determined according to the criteria in force.
- patients with osteoarticular disorders refers to patients who have at least two signs selected from inflammatory signs, fistulas and the proven presence of bacteria detected by puncture or blood culture.
- patients with hepatocellular insufficiency refers to patients with hepatitis, regardless of its cause (viral, toxic, drug or ischemic) and patients with cirrhosis of the liver.
- viral infection refers to a biological entity whether it is the hepatitis B virus (HBV), the hepatitis C virus (HCV), the human immunodeficiency virus (HIV), the virus herpes simplex virus (HSV), cytomegalovirus (CMV) requiring a host, usually a cell, which it uses the constituents to multiply.
- a "food supplement” is a foodstuff whose purpose is to supplement the normal diet and which constitutes a concentrated source of nutrients or other substances having a nutritional or physiological effect alone or in combination.
- the terms used include the constituent isomers, the stereoisomers of conformation, the enantiomers and the diastereoisomers of the chemical compound in question.
- cinnamaldehyde in the composition according to the invention, encompasses, unless otherwise indicated, cinnamaldehyde derivatives, formation dimers, in this case HCA-HCA, BCA-BCA, CA-CA.
- compositions below is a percentage by weight relative to the total mass of the active ingredients.
- Composition 1a beta-elemene (30%), lupeol (30%) and 2-hydroxy cinnamaldehyde (40%).
- Composition lb beta-elemene (30%), lupeol (30%) and 2'-benzoyloxycinnamaldehyde (40%).
- Composition 2 beta-elemene (30%), lupeol (30%), 2-hydroxy cinnamaldehyde (20%) and 2'-benzoyloxy cinnamaldehyde (20%).
- Composition 3a beta-elemene (50%), lupeol (30%), and 2-hydroxycinnamaldehyde (20%).
- Composition 3b beta-elemene (50%), lupeol (30%), and 2'-benzoyloxycinnamaldehyde (20%).
- Composition 4a beta-elemene (15%), lupeol (50%), beta-sitosterol (25%) and 2-hydroxy cinnamaldehyde (10%).
- Composition 4b beta-elemene (15%), lupeol (50%), beta-sitosterol (25%) and 2'-benzoyloxy cinnamaldehyde (10%).
- Composition 5a beta-elemene (20%), lupeol (20%), beta-sitosterol (40%) and 2-hydroxycinnamaldehyde (20%).
- Composition 5b beta-elemene (20%), lupeol (20%), beta-sitosterol (40%) and benzoyloxy cinnamaldehyde (20%).
- Composition 6a beta-elemene (25%), lupeol (35%), beta-sitosterol (15%) and 2 hydroxycinnamaldehyde (25%).
- Composition 6b beta-elemene (25%), lupeol (35%), beta-sitosterol (15%) and 2'-benzoyloxycinnamaldehyde (25%).
- Composition 7a beta-elemene (40%), lupeol (20%), beta-sitosterol (20%) and 2-hydroxycinnamaldehyde (20%).
- Composition 7b beta-elemene (40%), lupeol (20%), beta-sitosterol (20%) and benzoyloxycinnamaldehyde (20%).
- Hep3B Hepatocellular Carcinoma
- MCF-7 Breast Cancer
- DU-145 Prostate Cancer
- the stromal cells have also been studied in order to determine the impact of the composition according to the invention in the tumor microenvironment. These cells were maintained in DMEM, supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (MSP), containing penicillin, streptomycin and amphotericin B under standard growth conditions. (5% CO 2, 37 ° C, humidified atmosphere). The above compositions were dissolved and diluted in DMSO.
- FBS fetal bovine serum
- MSP antibiotic-antimycotic solution
- this pharmaceutical composition inhibits tumor stromal formation and hence metastatic spread and chemoresistance. It can, rightly, be used in the treatment of hepatocellular carcinoma, breast cancer, prostate cancer even at advanced stages.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1670645A FR3058058A1 (fr) | 2016-10-31 | 2016-10-31 | Composition pharmaceutique comprenant en tant que principe actif une combinaison de beta-elemene, de lupeol et du 2-hydroxycinnamaldehyde et/ou du 2-benzoyloxycinnalmaldehyde et/ou beta-sitosterol |
FR1670666A FR3058059B1 (fr) | 2016-10-31 | 2016-11-08 | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. |
FR1771115A FR3058060B1 (fr) | 2016-10-31 | 2017-10-23 | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. |
PCT/IB2017/056612 WO2018078539A1 (fr) | 2016-10-31 | 2017-10-25 | Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3429568A1 true EP3429568A1 (fr) | 2019-01-23 |
Family
ID=58401825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17808579.1A Withdrawn EP3429568A1 (fr) | 2016-10-31 | 2017-10-25 | Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240197755A1 (fr) |
EP (1) | EP3429568A1 (fr) |
KR (1) | KR20190077449A (fr) |
CN (1) | CN109562080B (fr) |
CA (1) | CA3043456A1 (fr) |
FR (2) | FR3058058A1 (fr) |
IL (1) | IL266623A (fr) |
MA (1) | MA44413A (fr) |
MX (1) | MX2019003685A (fr) |
WO (1) | WO2018078539A1 (fr) |
ZA (1) | ZA201902910B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109438166B (zh) * | 2018-11-08 | 2021-06-04 | 石药集团远大(大连)制药有限公司 | (1S,2S,4S)-β-榄香烯及其制备方法和应用 |
FR3100128B1 (fr) * | 2019-08-30 | 2022-02-18 | Nitcheu Guy Faustin Monkam | Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications |
WO2021110073A1 (fr) * | 2019-12-03 | 2021-06-10 | 成都康弘药业集团股份有限公司 | Composition pharmaceutique contenant de l'élémène, son procédé de préparation et son utilisation |
CN111909897B (zh) * | 2020-08-14 | 2021-12-21 | 宜兴市人民医院 | Ruvbl2在调控人脐带间质干细胞增殖和/或分化中的应用 |
CN113018312B (zh) * | 2021-01-11 | 2022-12-09 | 南开大学 | 一种降低肿瘤辐射抗性的纳米放疗增敏剂及其制备方法和应用 |
US20220362227A1 (en) * | 2021-05-11 | 2022-11-17 | Roseman University Of Health Sciences | Composition of phytonutrients for diabetes management |
KR20230167257A (ko) | 2022-05-31 | 2023-12-08 | 전남대학교산학협력단 | 1개 이상의 유효성분을 포함하는 신장섬유화증 예방, 개선 또는 치료용 조성물 |
CN117482049B (zh) * | 2023-12-29 | 2024-03-26 | 中国人民解放军总医院海南医院 | 一种抗肿瘤组合物 |
-
2016
- 2016-10-31 FR FR1670645A patent/FR3058058A1/fr active Pending
- 2016-11-08 FR FR1670666A patent/FR3058059B1/fr not_active Expired - Fee Related
-
2017
- 2017-10-25 CA CA3043456A patent/CA3043456A1/fr not_active Abandoned
- 2017-10-25 US US16/324,881 patent/US20240197755A1/en active Pending
- 2017-10-25 WO PCT/IB2017/056612 patent/WO2018078539A1/fr active Application Filing
- 2017-10-25 CN CN201780049274.1A patent/CN109562080B/zh active Active
- 2017-10-25 KR KR1020197015106A patent/KR20190077449A/ko not_active Application Discontinuation
- 2017-10-25 MX MX2019003685A patent/MX2019003685A/es unknown
- 2017-10-25 EP EP17808579.1A patent/EP3429568A1/fr not_active Withdrawn
- 2017-10-25 MA MA044413A patent/MA44413A/fr unknown
-
2019
- 2019-05-09 ZA ZA2019/02910A patent/ZA201902910B/en unknown
- 2019-05-14 IL IL266623A patent/IL266623A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20240197755A1 (en) | 2024-06-20 |
MA44413A (fr) | 2021-03-17 |
CA3043456A1 (fr) | 2018-05-03 |
KR20190077449A (ko) | 2019-07-03 |
FR3058058A1 (fr) | 2018-05-04 |
FR3058059B1 (fr) | 2020-07-10 |
ZA201902910B (en) | 2020-06-24 |
CN109562080B (zh) | 2022-12-20 |
MX2019003685A (es) | 2019-09-26 |
IL266623A (en) | 2019-07-31 |
CN109562080A (zh) | 2019-04-02 |
WO2018078539A1 (fr) | 2018-05-03 |
FR3058059A1 (fr) | 2018-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3429568A1 (fr) | Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications | |
US11712443B2 (en) | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | |
EP3206674B1 (fr) | Composition pharmaceutique multi-ingrédients destinée à être utilisée en cancérothérapie | |
EP3565536A1 (fr) | Composition pharmaceutique utilisée pour traiter les troubles du syndrome métabolique, les maladies infectieuses, et leurs complications. | |
TWI551288B (zh) | Antimicrobial activity enhancer for chemotherapeutic agents | |
CA3235078A1 (fr) | Methodes de traitement du cancer de l'endometre a l'aide d'extrait de chanvre | |
JP2020026434A (ja) | 癌治療剤 | |
JP7285001B2 (ja) | サフラナール製剤による肝臓癌治療の方法 | |
WO2018055136A1 (fr) | Utilisation des harringtonines dans le traitement du cancer du sein, notamment triple-négatif | |
FR3058060A1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
US9907852B2 (en) | Anticancer agent and side-effect-alleviating agent | |
EP2362772B1 (fr) | Association pharmaceutique contenant l'acide lipoïque et l'acide hydroxycitrique a titre de principes actifs | |
JP2023504202A (ja) | がんの再発を予防するための組成物および方法 | |
US20130116298A1 (en) | Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment | |
OA19197A (en) | Pharmaceutical composition for use in the theurapeutic treatment of cancer and complications of cancer. | |
KR20190124951A (ko) | Pfi-3를 포함하는 신장암의 예방 또는 치료용 조성물 | |
FR3065878A1 (fr) | Composition pharmaceutique, caracterisee en ce qu'elle comprend en tant que principe actif, une combinaison de beta-elemene, de lupeol, d'acemannane et d'un agent | |
TWI778414B (zh) | 一種包含安卓幸醇之組合物用於製備抑制肝癌細胞或肝癌幹細胞生長之藥物的用途 | |
FR3121038A1 (fr) | Composition pharmaceutique destinée à inhiber l’infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications. | |
CN114159427A (zh) | 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途 | |
EP3427740A1 (fr) | Nouveau traitement du cancer par une combinaison d'un dérivé phosphorique d'inositol et de chlorure de magnésium | |
OA18060A (fr) | Utilisation du sérum de mouton de ‘‘ race ’’ dans le traitement des maladies liées aux virus HIV. | |
KR20160150580A (ko) | 사우치논을 유효성분으로 포함하는 가족성 고콜레스테롤 혈증 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181019 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210217 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20221014 |